In terms of Regulation 30 read with Para A of Part A of Schedule III to SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby submit the updated Investor Presentation

Sudarshan Pharma submitted an updated investor presentation for April 2026 covering its specialty chemicals and pharmaceutical business. The company reported FY26 revenue of Rs 703 Cr, up 39% from Rs 505 Cr in FY25, with PAT of Rs 23.3 Cr (up 47%). Q4 FY26 showed revenue of Rs 221 Cr with PAT margin of 4.86%, improving from 2.48% in Q2 FY26. Key highlights include acquisitions of Ratna Lifesciences and Ishwari Healthcare (51%), new manufacturing units at Palghar and Hyderabad with GMP certification, a new CFO appointment (Sharad Kathawate), and proposed $20 million FCCB issuance. Export turnover for FY25-26 was Rs 21.85 Cr with a target of minimum Rs 100 Cr for FY26-27. Ratna Lifesciences turned around from Rs 0.87 Cr loss in FY23 to Rs 9.22 Cr PAT in FY25.